Anti-EGFR Recombinant Antibody (Nimotuzumab) (CAT#: TAB-710)

Recombinant humanized (from mouse) antibody expressed in CHO binding to human EGFR. Nimotuzumab is a humanized monoclonal antibody that as of 2014 had orphan status in the US and EU for glioma, and marketing approval in India, China, and other countries for squamous cell carcinomas of the head and neck.

Specific Inquiry Online Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 EGFR signal transduction and effects of EGFR inhibition on downstream targets.

Figure 1 EGFR signal transduction and effects of EGFR inhibition on downstream targets.

Scheme of EGFR signal transduction. Nimotuzumab and PD153035 are inhibitors of EGFR: Activation of EGFR results in activation of Akt signaling which relieves a TSC1/TSC2 as well as PRAS40 (via phosphorylation of Thr246)-mediated inhibition of mTORC1. RPS6 phosphorylation at Ser235/236 and Ser 240/244 is regulated by mTORC1.

Ronellenfitsch, M. W., Zeiner, P. S., Mittelbronn, M., Urban, H., Pietsch, T., Reuter, D., ... & Harter, P. N. (2018). Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma. Acta neuropathologica communications, 6(1), 81.

Figure 2 EGFR signal transduction and effects of EGFR inhibition on downstream targets.

Figure 2 EGFR signal transduction and effects of EGFR inhibition on downstream targets.

LNT-229 cells were incubated in serum-free DMEM for 90 min with vehicle (DMSO control), PD153035 (dissolved in DMSO), control solution for nimotuzumab (placebo solution of the trial) or 1 ?M nimotuzumab as indicated. Cellular lysates were analyzed by immunoblot with antibodies as indicated.

Ronellenfitsch, M. W., Zeiner, P. S., Mittelbronn, M., Urban, H., Pietsch, T., Reuter, D., ... & Harter, P. N. (2018). Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma. Acta neuropathologica communications, 6(1), 81.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Human
  • Derivation
  • Humanized (from mouse)
  • Type
  • IgG1 - kappa
  • Species Reactivity
  • Human
  • Applications
  • ELISA, IP, FC, FuncS, Neut, IF, IHC
  • Trade name
  • TheraCIM
  • CAS
  • 780758-10-3
  • Generic Name
  • nimotuzumab
  • Biological Half-Life
  • 62–304 hours
  • ATC Code
  • L01XC
  • MW
  • 147,659.45 g/mol
  • Related Disease
  • Glioma cancers

Product Property

  • Purity
  • >95.0%, determined by analysis by RP-HPLC & analysis by SDS-PAGE.
  • Storage
  • Store at -20°C. Avoid multiple freeze/thaw cycles.

Applications

  • Application Notes
  • The EGFR antibody has been reported in applications of Activ, WB.

Target

  • Alternative Names
  • nimotuzumab;TheraCIM;780758-10-3;hR3;h-R3;TheraCIM;BIOMAb EGFR;TheraCIM;Theraloc;CIMAher;EGFR;epidermal growth factor receptor;epidermal growth factor receptor (avian erythroblastic leukemia viral (v erb b) oncogene homolog) , ERBB;ERBB1;erythroblastic le

Related Resources

  • Biosimilar Overview
  • Related Diseases
  • Related Signaling Pathways
Please refer to Nimotuzumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Nimotuzumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Nimotuzumab"

Afuco™ Anti-EGFR ADCC Recombinant Antibody (Nimotuzumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized (from mouse) antibody expressed in CHO binding to human EGFR. Nimotuzumab is a humanized monoclonal antibody that as of 2014 had orphan status in the US and EU for glioma, and marketing approval in India, China, and other countries for squamous cell carcinomas of the head and neck.

See other products for "EGFR"

Chimeric Antibody

CAT Product Name Application Type
TAB-750 Anti-EGFR/HER1 Recombinant Antibody (Futuximab/Zatuximab) Neut, ELISA, IF, IP, FuncS, FC, WB IgG1 - kappa
TAB-0225CL Human Anti-EGFR Recombinant Antibody (TAB-0225CL) Block, Inhib, FuncS, Apop, In vivo Chimeric (Mouse/Human) IgG1
TAB-0225CL-F(E) Human Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-0225CL-F(E)) Block, Inhib, FuncS, Apop, In vivo Chimeric (Mouse/Human) Fab
TAB-272MZ-F(E) Human Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-272MZ-F(E)) FuncS Chimeric (mouse/human) Fab
TAB-302MZ-F(E) Human Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-302MZ-F(E)) ELISA Chimeric (mouse/human) Fab

Human Antibody

Fc Glycosylation

High-mannose Glycoform

CAT Product Name Application Type
Gly-055LC-1 Recombinant Anti-Human EGFR Antibody (Fc glycosylation/High-mannose glycosylated) ELISA Chimeric antibody (mouse/human)

Deglycosylated Antibody (Non-glycosylated IgGs)

CAT Product Name Application Type
Gly-167LC Recombinant Anti-Human EGFR Antibody (Non-glycosylated) ELISA Human antibody

Chicken IgY Antibody

CAT Product Name Application Type
BRD-0183MZ Chicken Anti-EGFR Polyclonal IgY WB Chicken antibody
BRD-0668MZ Chicken Anti-EGFR Polyclonal IgY WB Chicken antibody

Neutralizing Antibody

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-165 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Matuzumab), ADCC Enhanced Neut, ELISA, IF, IP, FuncS, FC ADCC enhanced antibody
AFC-TAB-464CQ Afuco™ Anti-EGFR ADCC Recombinant Antibody (Tomuzotuximab), ADCC Enhanced ELISA, IHC, FC, IP, IF, FuncS ADCC enhanced antibody
AFC-TAB-003 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Cetuximab), ADCC Enhanced IF, IP, Neut, FuncS, ELISA, FC ADCC enhanced antibody
AFC-TAB-040 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Zalutumumab), ADCC Enhanced ELISA, FC, IP, FuncS, IF, Neut ADCC enhanced antibody
AFC-TAB-119 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Necitumumab), ADCC Enhanced FC, IP, ELISA, Neut, FuncS, IF ADCC enhanced antibody

Submit a review or a question
There are currently no Customer reviews or questions for TAB-710. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

  • 0
  • 0
Cart
    Go to compare

    Go to compare